WhiteLab Secures $26M to Advance AI-Driven Gene Delivery
WhiteLab Genomics has closed a $26 million Series B round led by AVP to scale its AI-based approach to gene delivery for genomic medicines. The funding will expand the companys ALFRED platform, accelerate experimental validation of AI designs and grow a portfolio of licensable delivery components. WhiteLab aims to own and license key enabling technologies that make targeted genomic therapies more predictable and usable for biopharma partners.
AI Powers New “Bio-Assets” for Precision Medicine
At the center of WhiteLabs work is ALFRED, an AI platform that designs and optimizes gene delivery components computationally and then tests them in the lab. The company calls its outputs “bio-assets”: experimentally validated, IP-protected elements that can be plugged into therapeutic programs. Examples include engineered AAV capsids, non-viral lipid nanoparticles tuned for specific tissues, and programmable regulatory elements such as synthetic promoters and untranslated regions.
These bio-assets are created to address classic delivery bottlenecks: tissue targeting, immune recognition, payload capacity and expression control. By combining predictive models with iterative wet-lab validation, WhiteLab reduces the time and uncertainty of finding viable delivery solutions. That makes its assets attractive as licensed building blocks for drug developers rather than full product candidates.
Breakthroughs and Future Trajectory
One headline achievement from WhiteLab is an AI-designed AAV variant that demonstrates the ability to cross the blood-brain barrier with pronounced brain-to-liver targeting, a notable advance for CNS indications where delivery is a major obstacle. This kind of result begins to answer a common investor and researcher question: do computationally designed biological parts work in real systems? WhiteLabs reported experimental validation indicates they can.
Strategically, the company is focused on developing and licensing enabling technologies to pharma and biotech partners rather than advancing end-to-end medicines itself. With the new capital, WhiteLab plans to accelerate validation of its catalog, expand its proprietary library of bio-assets and scale commercial partnerships across North America, Europe and Asia. If ALFREDs predictive designs continue to hold up in vivo, WhiteLab could become a go-to source of delivery solutions that shorten development timelines and improve the targeting precision of genomic medicines.
